Clinical Trial Update: A Long-term Extension Study of PCI-32765 (Ibrutinib) [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study of ibrutinib (PCI-32765) in chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malignancies is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Graft-versus-host Disease
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: RECRUITING